Developing and deploying genomics technologies in support of cancer?and life sciences research.

Canada's Michael Smith Genome Sciences Centre (GSC) at BC Cancer is an international leader in genomics,?proteomics and bioinformatics?for precision medicine. By developing and deploying cutting-edge genome?sequencing, computational and analytical technology, we are creating?novel strategies to prevent and diagnose cancers and other diseases, uncovering new?therapeutic targets and helping the world realize the social and economic benefits of genome science.?

Technology Platform

The GSC?is available to support your research. We?guide experimental design, facilitate the processing of complex?biological samples and provide numerous sequencing and bioinformatic?services with the aim of making genomics accessible to the international scientific community. Explore our technology?platforms and services, and if you have?questions or would like to collaborate please fill out our?contact form?or speak directly?with one of our?platform leaders.

The GSC is?ISO27001?certified for information security management.

Scientific Research

The 15?faculty members at the GSC have a diverse range of expertise in genomics, bioinformatics, proteomics, epigenomics, immunogenetics, cancer biology, computer science and software development. Together, we apply our knowledge?to advance the global understanding of cancer and other diseases?with an ultimate aim toward improving?human health through disease prevention, the development of novel diagnostic strategies?and by uncovering new?therapeutic approaches, all the while helping the world to realize the social and economic benefits of genome?research.

Clinical Programs

The GSC is unique in that it fosters close collaborations between scientists and clinicians, allowing for an unencumbered focus on direct translational research. Through the Personalized OncoGenomics (POG) program, the GSC deploys whole genome and transcriptome?sequencing to inform therapeutic and management strategies for late-stage cancer patients in real time. The GSC is also certified by the?College of American Pathologists (CAP)?and?the?Diagnostic Accreditation Program (DAP)?to perform clinical genomic panel testing.


Please feel free to speak with one of our Platform Leaders directly:

Directors & Platform Leaders


Mar 18, 2021

A new method for analyzing silenced genes

Cancers are diseases of the genome. They can result from minor changes to single or a few base pairs, known as mutations, or from larger structural changes to the genome, including how it is packaged into chromosomes and manipulated by other molecules. Understanding how things have gone wrong in specific cancers can help scientists develop better prognostic tools and treatment strategies.


Prognostic significance of FCGR2B expression for the response of DLBCL patients to rituximab or obinutuzumab treatment

Blood Advances
Malgorzata Nowicka, Laura K Hilton, Margaret Ashton-Key, Chantal E Hargreaves, Chern Lee, Russell Foxall, Matthew J Carter, Stephen A Beers, Kathleen N Potter, Christopher R Bolen, Christian Klein, Andrea Knapp, Farheen Mir, Matthew Rose-Zerilli, Cathy Burton 0, Wolfram Klapper, David W Scott, Laurie H Sehn, Umberto Vitolo, Maurizio Martelli, Marek Trneny, Christopher K Rushton, Graham W Slack, Pedro Farinha, Jonathan C Strefford, Mikkel Z Oestergaard, Ryan D Morin, Mark S Cragg
Back to top